We are live on
!
Find out more
RC
Rangeley Capital Portfolio holdings
AUM
$103M
1-Year Est. Return
77.32%
This Fund
S&P 500
This Quarter
Est. Return
+20.64%
1 Year Est. Return
+77.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$83.8M
AUM Growth
-$9.56M
(-10%)
Cap. Flow
-$15.6M
Cap. Flow
% of AUM
-18.56%
Top 10 Holdings %
Top 10 Hldgs %
54.2%
Holding
117
New
40
Increased
13
Reduced
18
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$5.37M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$2.54M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
+$2.43M |
| 4 |
SKX
Skechers
SKX
|
+$2.07M |
| 5 |
Surgery Partners
SGRY
|
+$1.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burford Capital
BUR
|
+$3.92M |
| 2 |
Calumet Specialty Products
CLMT
|
+$2.55M |
| 3 |
Amplify Energy
AMPY
|
+$2.5M |
| 4 |
Liquidia Corp
LQDA
|
+$2.36M |
| 5 |
Par Pacific Holdings
PARR
|
+$2.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.94% |
| 2 | Energy | 12.53% |
| 3 | Real Estate | 8.38% |
| 4 | Consumer Discretionary | 7.77% |
| 5 | Materials | 7.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
26
DELISTED
Verve Therapeutics
VERV
| $696K | 0.83% |
+62,000
| New | +$353K |
|
27
Kura Oncology
KURA
$841M
| $669K | 0.8% |
+116,000
| New | +$711K |
|
28
LENSAR
LNSR
$66.4M
| $659K | 0.79% |
+50,000
| New | +$675K |
|
|
BPMC
29
DELISTED
Blueprint Medicines
BPMC
| $641K | 0.76% |
+5,000
| New | +$519K |
|
|
SEPN
30
Septerna Inc
SEPN
$1.49B
| $619K | 0.74% |
58,605
+5,655
| +11% | +$46.6K |
|
|
SWKH
31
DELISTED
SWK Holdings
SWKH
| $604K | 0.72% |
41,000
-14,101
| -26% | -$200K |
|
32
Sable Offshore Corp
SOC
$830M
| $550K | 0.66% |
+25,000
| New | +$582K |
|
|
HEPS
33
D-Market Electronic Services & Trading
HEPS
$1.05B
| $540K | 0.64% |
200,000
+55,674
| +39% | +$151K |
|
|
VIGL
34
DELISTED
Vigil Neuroscience
VIGL
| $539K | 0.64% |
+67,800
| New | +$304K |
|
|
BCYC
35
Bicycle Therapeutics
BCYC
$274M
| $521K | 0.62% |
+75,000
| New | +$597K |
|
|
RPTX
36
DELISTED
Repare Therapeutics
RPTX
| $494K | 0.59% |
+355,292
| New | +$464K |
|
37
SITE Centers
SITC
$234M
| $452K | 0.54% |
40,001
+27,804
| +228% | +$333K |
|
38
Theravance Biopharma
TBPH
$875M
| $372K | 0.44% |
+33,729
| New | +$328K |
|
|
ELEV
39
DELISTED
Elevation Oncology
ELEV
| $332K | 0.4% |
+905,289
| New | +$302K |
|
|
MLACR
40
DELISTED
Mountain Lake Acquisition Corp Right
MLACR
| $308K | 0.37% |
30,000
-50,000
| -63% | -$9.06K |
|
|
HLVX
41
DELISTED
HilleVax
HLVX
| $306K | 0.37% |
+153,790
| New | +$281K |
|
|
EPIX
42
DELISTED
ESSA Pharma
EPIX
| $289K | 0.34% |
+170,000
| New | +$287K |
|
|
BRSL
43
Brightstar Lottery PLC
BRSL
$1.93B
| $269K | 0.32% |
17,000
+2,751
| +19% | +$43.2K |
|
|
K
44
DELISTED
Kellanova
K
| $239K | 0.28% |
+3,000
| New | +$245K |
|
45
CALL
BridgeBio Pharma
BBIO
$16.5B
| $216K | 0.26% |
5,000
| – | – |
|
|
NBIS
46
Nebius Group N.V.
NBIS
$41.3B
| $216K | 0.26% |
3,900
-6,000
| -61% | -$207K |
|
|
PCSC
47
DELISTED
Perceptive Capital Solutions
PCSC
| $212K | 0.25% |
+20,000
| New | +$210K |
|
|
WOW
48
CALL
DELISTED
WideOpenWest
WOW
| $203K | 0.24% |
+50,000
| New | +$214K |
|
|
SHCO
49
DELISTED
Soho House & Co
SHCO
| $203K | 0.24% |
27,600
-6,534
| -19% | -$40.6K |
|
50
Atea Pharmaceuticals
AVIR
$355M
| $191K | 0.23% |
+53,000
| New | +$158K |
|
Similar funds
EFT
GWL
CC
ABLA
SPCM
OPAM
ES
IMT
Rangeley Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Rangeley Capital held 117 positions worth $83.8M, down 10% from $93.4M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Rangeley Capital withdrew a net $15.6M in Q2 2025, closing 44 positions and reducing 18 holdings. Its most notable exit was Liquidia Corp, an estimated $2.36M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 29% a quarter earlier, followed by Energy and Real Estate.
Against the trend, Rangeley Capital opened a new position in Prothena Corp worth $4.34M.
- Rangeley Capital's largest Q2 2025 buy was Prothena Corp: 715,367 shares worth $4.34M.
- Rangeley Capital added most to Sage Therapeutics in Q2 2025, an estimated $2.54M increase.
- Rangeley Capital's biggest Q2 2025 reduction was Burford Capital, cutting an estimated $3.92M.
- Rangeley Capital fully exited Liquidia Corp in Q2 2025, selling an estimated $2.36M.
- Rangeley Capital's ten largest holdings make up 54% of its $83.8M portfolio in Q2 2025.
- Rangeley Capital opened 40 new positions and closed 44 in Q2 2025.
- Rangeley Capital's portfolio value fell 10% quarter-over-quarter to $83.8M.
Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.